Xeris Biopharma Holdings (XERS) Cash & Equivalents (2020 - 2026)

Xeris Biopharma Holdings' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $111.8 million for Q1 2026.

• Quarterly Cash & Equivalents rose 91.22% year-over-year to $111.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $111.8 million (up 91.22% YoY) and the FY2025 annual result came in at $111.0 million, up 55.04% from the prior year.
• Cash & Equivalents was $111.8 million for Q1 2026 at Xeris Biopharma Holdings, up from $111.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $122.0 million in Q4 2022 and bottomed at $46.1 million in Q3 2023.
• A 5-year average of $76.4 million and a median of $67.4 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 51.57% — and 2026, when it soared 91.22%.
• Xeris Biopharma Holdings' Cash & Equivalents stood at $122.0 million in 2022, then plunged by 44.7% to $67.4 million in 2023, then gained by 6.19% to $71.6 million in 2024, then jumped by 55.04% to $111.0 million in 2025, then gained by 0.64% to $111.8 million in 2026.
• Business Quant data shows XERS's Cash & Equivalents at $111.8 million in Q1 2026, $111.0 million in Q4 2025, and $91.6 million in Q3 2025.